WGc-0201 + Tislelizumab for high-risk liver cancer after treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two drugs (WGc-0201 plus Tislelizumab) to help prevent liver cancer from coming back after you've had surgery or ablation. It is for people with hepatitis B who are at high risk for recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed type of liver cancer called hepatocellular carcinoma (HCC).
- You have had surgery to remove the tumor, or a needle-based ablation (like radiofrequency or microwave), and no cancer was left behind.
- Your doctor considers you at high risk for the cancer returning or spreading after that treatment.
- You test positive for hepatitis B surface antigen (HBsAg).
- You have no cancer found outside the liver (by CT or MRI).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs: tislelizumab (an immunotherapy that helps your immune system attack cancer) and huaier granule (a traditional Chinese medicine extract). It is for people with advanced liver cancer that cannot be removed by surgery and who have not had other systemic treatments before.
This trial tests a new immunotherapy drug (GKL-006) combined with a standard treatment called TACE (which blocks blood flow to the tumor) for people with liver cancer that cannot be removed by surgery. The goal is to see if adding this drug helps shrink tumors more than TACE alone.
This trial tests a new drug that combines two immunotherapy approaches (PD-1 and IL-2) given before surgery to treat hepatocellular carcinoma (liver cancer) that has come back 3 months to 2 years after your first surgery. The goal is to shrink the tumor and help your body's immune system fight the cancer.
This trial tests combining three drugs (atezolizumab, bevacizumab, and tocilizumab) to see if they can help people with advanced liver cancer that cannot be removed with surgery. It aims to shrink tumors and improve outcomes for patients who have not had prior systemic therapy.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
This trial studies whether combining two medicines (tislelizumab and sitravatinib) given after curative liver cancer surgery can help prevent the cancer from coming back. It is for people with liver cancer at high risk of recurrence, who have fully recovered from surgery and have no spread beyond the liver.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.